argenx SE’s (ARGX) Share Price Increased By 28% Due to Several Factors
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy outperformed the Russell Midcap Growth Index and returned -4.11% (net) while the index return was -5.22%. The third quarter saw a decline in global equities markets, although they have held up positive year-to-date. In addition, please check the fund’s top five holdings to know its best picks in 2023.
TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted stocks like argenx SE (NASDAQ:ARGX) in the third quarter 2023 investor letter. Headquartered in Amsterdam, the Netherlands, argenx SE (NASDAQ:ARGX) is a biotechnology company. On December 15, 2023, argenx SE (NASDAQ:ARGX) stock closed at $463.00 per share. One-month return of argenx SE (NASDAQ:ARGX) was -5.38%, and its shares gained 22.70% of their value over the last 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $27.353 billion.
TimesSquare Capital U.S. Mid Cap Growth Strategy made the following comment about argenx SE (NASDAQ:ARGX) in its Q3 2023 investor letter:
"Our preference within Health Care is for novel therapies to address unmet medical needs, specialized providers, and innovators. argenx SE (NASDAQ:ARGX) is a global immunology company focused on autoimmune diseases. Their share price advanced 28% after outpacing estimates and aided by sales of Vyvgart for treating myasthenia gravis. Management also gave an encouraging update on clinical readouts and their expanding pipeline."
A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.
argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 48 hedge fund portfolios held Argenx SE (NASDAQ:ARGX) at the end of third quarter which was 47 in the previous quarter.
We discussed argenx SE (NASDAQ:ARGX) in another article and shared the list of largest pharmaceutical companies in the world. In addition, please check out our hedge fund investor letters Q3 2023 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
Disclosure: None. This article is originally published at Insider Monkey.
